Edit Symbol List
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Company Description (as filed with the SEC)
We are a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing proprietary therapeutics that target cancer stem cells, or CSCs, and tumor bulk. We are currently developing two clinical stage product candidates, SL-401 and SL-701, as well as a pipeline of preclinical candidates that include SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor, or IL-3R, present on CSCs and tumor bulk of a variety of hematologic cancers. In July 2014, we opened a corporate sponsored investigational new drug, or IND, with the FDA. ... More ...
Where does STML fit in the risk graph?
|Annual EPS Est:||$-2.23|
|Quarterly EPS Est:||-0.45|